Emmanuel Heilmann
Overview
Explore the profile of Emmanuel Heilmann including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
161
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Costacurta F, Rauch S, von Laer D, Heilmann E
Curr Protoc
. 2024 Dec;
4(12):e70074.
PMID: 39711492
Antiviral drugs are essential medications to save the lives of infected people. However, they are under constant threat to become ineffective as viruses evolve quickly. Studying the development of resistance...
2.
Rauch S, Costacurta F, von Laer D, Heilmann E
Curr Protoc
. 2024 Nov;
4(11):e70062.
PMID: 39570195
Protease inhibitors are among the most powerful antiviral drugs. They have been used successfully against viruses, such as the human immunodeficiency virus (HIV), hepatitis C virus (HCV) and severe acute...
3.
Costacurta F, Dodaro A, Bante D, Schoppe H, Peng J, Sprenger B, et al.
PLoS Pathog
. 2024 Sep;
20(9):e1012522.
PMID: 39259728
Nirmatrelvir was the first protease inhibitor specifically developed against the SARS-CoV-2 main protease (3CLpro/Mpro) and licensed for clinical use. As SARS-CoV-2 continues to spread, variants resistant to nirmatrelvir and other...
4.
Rauch S, Costacurta F, Schoppe H, Peng J, Bante D, Erisoez E, et al.
Antiviral Res
. 2024 Jul;
231:105969.
PMID: 39053514
In the SARS-CoV-2 pandemic, the so far two most effective approved antivirals are the protease inhibitors nirmatrelvir, in combination with ritonavir (Paxlovid) and ensitrelvir (Xocova). However, antivirals and indeed all...
5.
Krismer L, Schoppe H, Rauch S, Bante D, Sprenger B, Naschberger A, et al.
Npj Viruses
. 2024 Jun;
2(1):23.
PMID: 38933182
The Middle East Respiratory Syndrome Coronavirus (MERS-CoV) is an epidemic, zoonotically emerging pathogen initially reported in Saudi Arabia in 2012. MERS-CoV has the potential to mutate or recombine with other...
6.
Costacurta F, Dodaro A, Bante D, Schoppe H, Sprenger B, Moghadasi S, et al.
bioRxiv
. 2023 Oct;
PMID: 37808638
Nirmatrelvir was the first protease inhibitor (PI) specifically developed against the SARS-CoV-2 main protease (3CL/M) and licensed for clinical use. As SARS-CoV-2 continues to spread, variants resistant to nirmatrelvir and...
7.
Moghadasi S, Heilmann E, Khalil A, Nnabuife C, Kearns F, Ye C, et al.
Sci Adv
. 2023 Mar;
9(13):eade8778.
PMID: 36989354
Vaccines and drugs have helped reduce disease severity and blunt the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, ongoing virus transmission, continuous evolution, and increasing selective pressures...
8.
Heilmann E, Costacurta F, Moghadasi S, Ye C, Pavan M, Bassani D, et al.
Sci Transl Med
. 2022 Oct;
15(678):eabq7360.
PMID: 36194133
Protease inhibitors are among the most powerful antiviral drugs. Nirmatrelvir is the first protease inhibitor specifically developed against the SARS-CoV-2 protease 3CL that has been licensed for clinical use. To...
9.
Moghadasi S, Heilmann E, Khalil A, Nnabuife C, Kearns F, Ye C, et al.
bioRxiv
. 2022 Aug;
PMID: 35982678
Vaccines and drugs have helped reduce disease severity and blunt the spread of SARS-CoV-2. However, ongoing virus transmission, continuous evolution, and increasing selective pressures have the potential to yield viral...
10.
Heilmann E, Costacurta F, Geley S, Mogadashi S, Volland A, Rupp B, et al.
Commun Biol
. 2022 Apr;
5(1):391.
PMID: 35478219
Protease inhibitors are among the most powerful antiviral drugs. However, for SARS-CoV-2 only a small number of protease inhibitors have been identified thus far and there is still a great...